FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

GENFIT announced that the US FDA has granted orphan drug designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma.
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News